Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole 2M LAI (Abilify Asimtufii) Bridging Study
NCT04030143Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aripiprazole in schizophrenia, bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Aug 2019; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT04030143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030143.